These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38226936)

  • 1. Spesolimab for the treatment of generalized pustular psoriasis: real life experience.
    Dattola A; Taliano A; Rallo A; Pellacani G; Richetta AG
    Ital J Dermatol Venerol; 2024 Feb; 159(1):61-62. PubMed ID: 38226936
    [No Abstract]   [Full Text] [Related]  

  • 2. Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis.
    Burden AD
    Expert Rev Clin Immunol; 2023 May; 19(5):473-481. PubMed ID: 36960829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation.
    Potestio L; Camela E; Cacciapuoti S; Martora F; Guerriero L; Fornaro L; Ruggiero A; Megna M
    Expert Opin Drug Saf; 2023; 22(11):1003-1010. PubMed ID: 37768729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients.
    Bukhari T; Markovina M; Abduelmula A; Rankin BD; Vender R; Yeung J; Devani AR; Prajapati VH
    Skin Therapy Lett; 2024 Jan; 29(1):1-4. PubMed ID: 38271532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study.
    Elewski BE; Lebwohl MG; Anadkat MJ; Barker J; Ghoreschi K; Imafuku S; Mrowietz U; Li L; Quaresma M; Thoma C; Bachelez H
    J Am Acad Dermatol; 2023 Jul; 89(1):36-44. PubMed ID: 36870370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Remission of recalcitrant generalized pustular psoriasis under interleukin-36 receptor inhibitor spesolimab].
    Müller VL; Kreuter A
    Dermatologie (Heidelb); 2023 May; 74(5):356-359. PubMed ID: 36943426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double-blind, placebo-controlled Effisayil™ 1 study.
    Morita A; Tsai TF; Yee EYW; Okubo Y; Imafuku S; Zheng M; Li L; Quaresma M; Thoma C; Choon SE
    J Dermatol; 2023 Feb; 50(2):183-194. PubMed ID: 36282833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trial of Spesolimab for Generalized Pustular Psoriasis.
    Bachelez H; Choon SE; Marrakchi S; Burden AD; Tsai TF; Morita A; Navarini AA; Zheng M; Xu J; Turki H; Anadkat MJ; Rajeswari S; Hua H; Vulcu SD; Hall D; Tetzlaff K; Thoma C; Lebwohl MG;
    N Engl J Med; 2021 Dec; 385(26):2431-2440. PubMed ID: 34936739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis.
    Baum P; Visvanathan S; Garcet S; Roy J; Schmid R; Bossert S; Lang B; Bachelez H; Bissonnette R; Thoma C; Krueger JG
    J Allergy Clin Immunol; 2022 Apr; 149(4):1402-1412. PubMed ID: 34678325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spesolimab: A Novel Treatment for Pustular Psoriasis.
    Ratnarajah K; Jfri A; Litvinov IV; Netchiporouk E
    J Cutan Med Surg; 2020; 24(2):199-200. PubMed ID: 32208020
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment of recalcitrant generalized pustular psoriasis of pregnancy with spesolimab.
    Yang C; Wang Y; Li R; Tu P; Wang R
    J Dermatolog Treat; 2024 Dec; 35(1):2334791. PubMed ID: 38565205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spesolimab in the treatment of generalized pustular psoriasis: a critically appraised research paper.
    Ali F; Smith CH; Mahil SK
    Br J Dermatol; 2023 Feb; 188(3):328-329. PubMed ID: 36763745
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
    Morita A; Strober B; Burden AD; Choon SE; Anadkat MJ; Marrakchi S; Tsai TF; Gordon KB; Thaçi D; Zheng M; Hu N; Haeufel T; Thoma C; Lebwohl MG
    Lancet; 2023 Oct; 402(10412):1541-1551. PubMed ID: 37738999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of severe generalized pustular psoriasis due to tuberculosis screening delay for spesolimab initiation.
    Hackley M; Thampy D; Waseh S; Feldman SR; Blauvelt A; Weinberg JM; Schwartzman S; Liao W; Prussick R; Cohen JM; Hsu S;
    J Am Acad Dermatol; 2024 Feb; 90(2):408-410. PubMed ID: 37821053
    [No Abstract]   [Full Text] [Related]  

  • 15. Spesolimab: First Approval.
    Blair HA
    Drugs; 2022 Nov; 82(17):1681-1686. PubMed ID: 36418672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study.
    Burden AD; Okubo Y; Zheng M; Thaçi D; van de Kerkhof P; Hu N; Quaresma M; Thoma C; Choon SE
    Exp Dermatol; 2023 Aug; 32(8):1279-1283. PubMed ID: 37140190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spesolimab rapidly treats generalized pustular psoriasis and improves the skin immune microenvironment in Chinese patients.
    Lu J; Yu Q; Huang D; Hu Y; Zhong X; Zheng J; Ding Y; Gao Y; Li Y; Shi Y
    Clin Immunol; 2024 Aug; 265():110280. PubMed ID: 38880199
    [No Abstract]   [Full Text] [Related]  

  • 18. Severe flare of generalized pustular psoriasis treated with spesolimab, an IL-36-directed monoclonal antibody.
    Mateeva V; Vasilev P; Gospodinova K; Gincheva V; Shahid M; Kostova P; Lukanov T; Yordanova I
    J Dtsch Dermatol Ges; 2024 May; 22(5):696-699. PubMed ID: 38619312
    [No Abstract]   [Full Text] [Related]  

  • 19. Spesolimab treatment in a patient with generalized pustular psoriasis: a case report with 12-month follow-up and literature review.
    Cardenas-de la Garza JA; Zazueta-López RM; Garza-Elizondo AK; Flores-Gutierrez DP; Welsh E
    Clin Exp Dermatol; 2024 Feb; 49(3):286-288. PubMed ID: 37966307
    [No Abstract]   [Full Text] [Related]  

  • 20. Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis.
    Morita A; Choon SE; Bachelez H; Anadkat MJ; Marrakchi S; Zheng M; Tsai TF; Turki H; Hua H; Rajeswari S; Thoma C; Burden AD
    Dermatol Ther (Heidelb); 2023 Jan; 13(1):347-359. PubMed ID: 36333618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.